Oxaliplatin Reacts with DMSO Only in the Presence of Water

Overview

Journal Dalton Trans

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2017 Jun 28

PMID 28654098

Citations 7

Authors

Hristo P Varbanov

Daniel Ortiz

Doris Hofer

Laure Menin

Mathea S Galanski

Bernhard K Keppler

Paul J Dyson

Affiliations

Soon will be listed here.

Abstract

Herein we show that oxaliplatin reacts rapidly with DMSO in aqueous solutions, despite being stable in pure DMSO and pure water. Furthermore, the reactivity of the clinically applied Pt(ii) drugs in water/DMSO and PBS/DMSO mixtures, and the nature of the species formed were investigated by MS, NMR and RP-HPLC techniques.

Citing Articles

Selective Targeting of Regulated Rhabdomyosarcoma Cells by Trinuclear Ruthenium(II)-Arene Complexes.

Welsh A, Serala K, Prince S, Smith G J Med Chem. 2024; 67(8):6673-6686.

PMID: 38569098 PMC: 11056987. DOI: 10.1021/acs.jmedchem.4c00256.

A New Manganese Superoxide Dismutase Mimetic Improves Oxaliplatin-Induced Neuropathy and Global Tolerance in Mice.

Prieux-Klotz C, Chedotal H, Zoumpoulaki M, Chouzenoux S, Chene C, Lopez-Sanchez A Int J Mol Sci. 2022; 23(21).

PMID: 36361753 PMC: 9658974. DOI: 10.3390/ijms232112938.

Identification of Platinum(II) Sulfide Complexes Suitable as Intramuscular Cyanide Countermeasures.

Behymer M, Mo H, Fujii N, Suresh V, Chan A, Lee J Chem Res Toxicol. 2022; 35(11):1983-1996.

PMID: 36201358 PMC: 9682522. DOI: 10.1021/acs.chemrestox.2c00157.

Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agents.

Nabiyeva T, Roufosse B, Odachowski M, Baumgartner J, Marschner C, Verma A ACS Omega. 2021; 6(29):19252-19268.

PMID: 34337263 PMC: 8320079. DOI: 10.1021/acsomega.1c02665.

Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.

Camp J, Nyamini S, Scott F RSC Med Chem. 2021; 11(1):111-117.

PMID: 33479610 PMC: 7522793. DOI: 10.1039/c9md00341j.

References

Jerremalm E, Eksborg S, Ehrsson H . Hydrolysis of oxaliplatin-evaluation of the acid dissociation constant for the oxalato monodentate complex. J Pharm Sci. 2003; 92(2):436-8. DOI: 10.1002/jps.10306. View

Dernell W, Straw R, Withrow S, Powers B, Fujita S, Yewey G . Apparent interaction of dimethyl sulfoxide with cisplatin released from polymer delivery devices injected subcutaneously in dogs. J Drug Target. 1998; 5(5):391-6. DOI: 10.3109/10611869808997866. View

Petrovic P, Grimme S, Zaric S, Pfeffer M, Djukic J . Experimental and theoretical investigations of the self-association of oxaliplatin. Phys Chem Chem Phys. 2014; 16(28):14688-98. DOI: 10.1039/c4cp01500b. View

Yi Y, Bae I . Effects of solvents on in vitro potencies of platinum compounds. DNA Repair (Amst). 2011; 10(11):1084-5. PMC: 3508678. DOI: 10.1016/j.dnarep.2011.09.008. View

Massart C, Le Tellier C, Gibassier J, Leclech G, Nicol M . Modulation by dimethyl sulphoxide of the toxicity induced by cis-diamminedichloroplatinum in cultured thyrocytes. Toxicol In Vitro. 2010; 7(1):87-94. DOI: 10.1016/0887-2333(93)90116-m. View

Di Pasqua A, Kerwood D, Shi Y, Goodisman J, Dabrowiak J . Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association. Dalton Trans. 2011; 40(18):4821-5. DOI: 10.1039/c0dt01758b. View

Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H . Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004; 21(5):891-4. DOI: 10.1023/b:pham.0000026444.67883.83. View

Hall M, Telma K, Chang K, Lee T, Madigan J, Lloyd J . Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 2014; 74(14):3913-22. PMC: 4153432. DOI: 10.1158/0008-5472.CAN-14-0247. View

Olszewski U, Hamilton G . A better platinum-based anticancer drug yet to come?. Anticancer Agents Med Chem. 2010; 10(4):293-301. DOI: 10.2174/187152010791162306. View

10.

Pereira D, Williams J . Origin and evolution of high throughput screening. Br J Pharmacol. 2007; 152(1):53-61. PMC: 1978279. DOI: 10.1038/sj.bjp.0707373. View

11.

Cheff D, Hall M . A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research. J Med Chem. 2017; 60(11):4517-4532. DOI: 10.1021/acs.jmedchem.6b01351. View

12.

Barnham K, Djuran M, Murdoch P, Ranford J, Sadler P . Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. Inorg Chem. 1996; 35(4):1065-1072. DOI: 10.1021/ic950973d. View

13.

Summa N, Soldatovic T, Dahlenburg L, Bugarcic Z, van Eldik R . The impact of different chelating leaving groups on the substitution kinetics of mononuclear Pt(II)(1,2-trans-R,R-diaminocyclohexane)(X-Y) complexes. J Biol Inorg Chem. 2007; 12(4):461-75. DOI: 10.1007/s00775-006-0200-z. View

14.

Balakin K, Savchuk N, Tetko I . In silico approaches to prediction of aqueous and DMSO solubility of drug-like compounds: trends, problems and solutions. Curr Med Chem. 2006; 13(2):223-41. DOI: 10.2174/092986706775197917. View

15.

Apps M, Choi E, Wheate N . The state-of-play and future of platinum drugs. Endocr Relat Cancer. 2015; 22(4):R219-33. DOI: 10.1530/ERC-15-0237. View

16.

Summa N, Schiessl W, Puchta R, van Eikema Hommes N, van Eldik R . Thermodynamic and kinetic studies on reactions of Pt(II) complexes with biologically relevant nucleophiles. Inorg Chem. 2006; 45(7):2948-59. DOI: 10.1021/ic051955r. View

17.

Wheate N, Walker S, Craig G, Oun R . The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010; 39(35):8113-27. DOI: 10.1039/c0dt00292e. View